OnTimeBio
Disease Detection and Monitoring
Company Overview
Snapshot
Founded in January 2017 by Yuval Dor and Ariel Cohen, OnTimeBio operates with 1–10 employees. The company is developing a highly sensitive blood test for disease detection and monitoring, utilizing advanced computational approaches with genomic and epigenomic methods.
Business overview
OnTimeBio is a Health Tech & Life Sciences company focused on developing a highly sensitive blood test for the timely detection and monitoring of various diseases. Its core technology leverages advanced computational approaches combined with genomic and epigenomic methods to provide quantitative and precise readouts of tissue dynamics across human organs. The company aims to apply this technology across multiple disease areas, including cancer, metabolic, autoimmune, and neurodegenerative diseases, to reduce patient suffering, enable better treatment outcomes, and lower healthcare costs. Additionally, the technology offers a tool for developers of novel therapeutics to improve patient stratification and monitor responses to new therapies.
Log in to access full profile ›Company Intelligence Q&A
- What is OnTimeBio's primary focus?
- OnTimeBio is focused on developing a highly sensitive blood test for the timely detection and monitoring of diseases, utilizing advanced computational approaches with genomic and epigenomic methods.
- When was OnTimeBio founded?
- OnTimeBio was founded in January 2017.
- Who are the founders of OnTimeBio?
- OnTimeBio was founded by Yuval Dor and Ariel Cohen.
- What technology does OnTimeBio use for disease detection?
- OnTimeBio's product utilizes advanced computational approaches with genomic and epigenomic methods to enable a quantitative and exact readout of tissue dynamics across human organs.
- Which diseases does OnTimeBio's technology aim to address?
- OnTimeBio's technology is applicable across multiple diseases, including cancer, metabolic, autoimmune, and neurodegenerative diseases.